Cited by 57Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsNeurological Disease Mechanisms and Treatments

Review: Experimental manipulations of microglia in mouse models of A lzheimer's pathology: activation reduces amyloid but hastens tau pathology

Open access
Lee, D. C., Rizer, J., Hunt, J. B., Selenica, M.‐L. B., Gordon, M. N., Morgan, D.·2013·Neuropathology and Applied Neurobiology

Abstract

The inflammation hypothesis of A lzheimer's pathogenesis has directed much scientific effort towards ameliorating this disease. The development of mouse models of amyloid deposition permitted direct tests of the proposal that amyloid‐activated microglia could cause neurodegeneration in vivo. Many approaches to manipulating microglial activation have been applied to these mouse models, and are the subject of this review. In general, these results do not support a direct neuricidal action of microglia in mouse amyloid models under any activation state. Some of the manipulations cause both a reduction in pathology and a reduction in microglial activation. However, at least for agents like ibuprofen, this outcome may result from a direct action on amyloid production, and a reduction in the microglial‐provoking amyloid deposits, rather than from reduced microglial activation leading to a decline in amyloid deposition. Instead, a surprising number of the experimental manipulations which increase microglial activation lead to enhanced clearance of the amyloid deposits. Both the literature and new data presented here suggest that either classical or alternative activation of microglia can lead to enhanced amyloid clearance. However, a limited number of studies comparing the same treatments in amyloid‐depositing vs. tau‐depositing mice find the opposite effects. Treatments that benefit amyloid pathology accelerate tau pathology. This observation argues strongly that potential treatments be tested for impact on both amyloid and tau pathology before consideration of testing in humans.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/nan.12002

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Studies on the role of TLRs in microglial activation have produced conflicting results.

    “studies elucidating the role of TLRs in microglial activation have yielded conflicting results (109).”

    From Microglia in Alzheimer's disease (2017) · cites this paper as [109]

  • TLR4 stimulation increases tau-related pathology in 3xTgAD and rTg4510 mice.

    “A drawback of TLR4 stimulation was the observed increase in taurelated pathology in 3xTgAD and rTg4510 mice (109).”

    From Microglia in Alzheimer's disease (2017) · cites this paper as [109]

  • IL-1β enhances amyloid-beta pathology and increases tau pathology.

    “IL-1β, a key cytokine of the innate immune response, was shown to enhance Aβ pathology (126), as well as increase tau pathology (109).”

    From Microglia in Alzheimer's disease (2017) · cites this paper as [109]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lee, D. C., Rizer, J., Hunt, J. B., Selenica, M. ‐. B., Gordon, M. N., & Morgan, D.
Affiliations
University of South Florida (US)
Corresponding author
Morgan, D.
Venue
Neuropathology and Applied Neurobiology
Publisher
Wiley
Published
2013-01-22
Volume
39
Issue
1
Pages
69-85
ISSN
  • 0305-1846 (ISSN-L)
  • 1365-2990
OpenAlex
W1960212508
Cited by
57
References
116
Citations by year
2025: 2 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 1 · 2018: 1 · 2017: 4 · 2016: 4 · 2015: 11 · 2014: 8 · 2013: 6
FWCI
0.87
Type
journal article
Language
en
Open access
Locations
  • Neuropathology and Applied Neurobiology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Aging (AG 15490, AG04418, P01AG004418, R01AG015490)
  • National Institute of Neurological Disorders and Stroke (NS76308, R01NS076308)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
Alzheimer's disease, microglial activation, amyloid-beta, tau pathology, neuroinflammation, ibuprofen, amyloid clearance, mouse models of Alzheimer's disease, neurodegeneration
MeSH terms
Alzheimer Disease, Animals, Disease Models, Animal, Amyloid beta-Peptides, tau Proteins, Microglia, Mice, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review